Enlivex Therapeutics Financials Indicate Net Loss
Company Announcements

Enlivex Therapeutics Financials Indicate Net Loss

Enlivex (ENLV) has released an update.

Enlivex Therapeutics Ltd. reports its financial status, showing a total asset decrease from $36,831 thousand to $31,902 thousand between December 31, 2023, and June 30, 2024. The balance sheet reveals a drop in current assets and an accumulated deficit increase, reflecting a challenging fiscal period with a net loss of $7,236 thousand for the six months ended June 30, 2024. These unaudited figures highlight Enlivex’s financial movements and potential concerns for investors.

For further insights into ENLV stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskEnlivex Initiates Promising Trial for Psoriatic Arthritis
TheFlyEnlivex completes dosing, follow-up for first patient in study of Allocetra
TipRanks Auto-Generated NewsdeskEnlivex Advances Allocetra Trial for Knee Osteoarthritis
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App